Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting. The company also develops SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; SPR720, an oral antibiotic, which is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SPRO
CUSIPN/A
Phone857-242-1600
Debt
Debt-to-Equity RatioN/A
Current Ratio13.68
Quick Ratio13.68
Price-To-Earnings
Trailing P/E Ratio-0.75
Forward P/E Ratio-3.99
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.98 million
Price / Sales96.53
Cash FlowN/A
Price / CashN/A
Book Value$5.91 per share
Price / Book2.25
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees35
Outstanding Shares14,370,000
Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions
What is Spero Therapeutics' stock symbol?
Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."
How were Spero Therapeutics' earnings last quarter?
Spero Therapeutics Inc (NASDAQ:SPRO) posted its quarterly earnings results on Thursday, May, 10th. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.46. The company had revenue of $1.15 million for the quarter, compared to analysts' expectations of $0.20 million. View Spero Therapeutics' Earnings History.
What price target have analysts set for SPRO?
6 analysts have issued 12 month price targets for Spero Therapeutics' shares. Their predictions range from $26.00 to $30.00. On average, they expect Spero Therapeutics' stock price to reach $27.75 in the next twelve months. View Analyst Ratings for Spero Therapeutics.
What are Wall Street analysts saying about Spero Therapeutics stock?
Here are some recent quotes from research analysts about Spero Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "We rate SPRO Overweight. Spero has three programs that target multi-billion- dollar commercial opportunities (SPR994/oral carbapenem, SPR741 and SPR206/ IV potentiators, and SPR720/NTM program) which focus on unmet needs inside and outside the hospital. As the company advances its pipeline toward commercialization, we expect upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations to drive SPRO’s stock higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $27 12-month price target." (6/11/2018)
- 2. According to Zacks Investment Research, "Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. " (2/21/2018)
Who are some of Spero Therapeutics' key competitors?
Some companies that are related to Spero Therapeutics include AMAG Pharmaceuticals (AMAG), Theratechnologies (THERF), Evolus (EOLS), NuCana (NCNA), Urogen Pharma (URGN), Inflarx (IFRX), Abeona Therapeutics (ABEO), Vectura Group (VEGPF), Arcus Biosciences (RCUS), Rhythm Pharmaceuticals (RYTM), Homology Medicines (FIXX), CannTrust (CNTTF), Odonate Therapeutics (ODT), Adamas Pharmaceuticals (ADMS) and Geron (GERN).
Who are Spero Therapeutics' key executives?
Spero Therapeutics' management team includes the folowing people:
- Mr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 37)
- Dr. Thomas R. Parr Jr., Ph.D., Chief Scientific Officer (Age 64)
- Mr. Joel D. Sendek, CFO & Treasurer (Age 51)
- Ms. Cristina Larkin, Chief Operating Officer (Age 48)
- Ms. Sharon Klahre, Director of Investor Relations
When did Spero Therapeutics IPO?
(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.
When did Spero Therapeutics' lock-up period expire?
Spero Therapeutics' lock-up period expired on Tuesday, May 1st. Spero Therapeutics had issued 5,500,000 shares in its IPO on November 2nd. The total size of the offering was $77,000,000 based on an initial share price of $14.00. Since the expiration of Spero Therapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Has Spero Therapeutics been receiving favorable news coverage?
Headlines about SPRO stock have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spero Therapeutics earned a news impact score of 0.20 on Accern's scale. They also gave headlines about the company an impact score of 45.99 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Spero Therapeutics' major shareholders?
Spero Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (7.30%), JPMorgan Chase & Co. (1.78%), BlackRock Inc. (1.76%), DAFNA Capital Management LLC (0.21%) and Millennium Management LLC (0.08%). Company insiders that own Spero Therapeutics stock include Casper Breum, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View Institutional Ownership Trends for Spero Therapeutics.
Which major investors are buying Spero Therapeutics stock?
SPRO stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., DAFNA Capital Management LLC, BVF Inc. IL, BlackRock Inc. and Millennium Management LLC. Company insiders that have bought Spero Therapeutics stock in the last two years include Casper Breum, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View Insider Buying and Selling for Spero Therapeutics.
How do I buy shares of Spero Therapeutics?
Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spero Therapeutics' stock price today?
One share of SPRO stock can currently be purchased for approximately $13.30.
How big of a company is Spero Therapeutics?
Spero Therapeutics has a market capitalization of $193.98 million and generates $1.98 million in revenue each year. The company earns $-38,740,000.00 in net income (profit) each year or ($17.82) on an earnings per share basis. Spero Therapeutics employs 35 workers across the globe.
How can I contact Spero Therapeutics?
Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]
MarketBeat Community Rating for Spero Therapeutics (SPRO)
MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote "Outperform" if you believe SPRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
